Profusa, Inc. - Common Stock (PFSA)

EU commercialization expected in early 2026; U.S. entry and expanded indications to follow as digital-health pioneer advances tissue-integrated biosensor platform

Signal Advance, Inc. (OTC: SIGL ) today announced a new milestone in the evolution of cybersecurity: successful validation of its Analog Guard® encryption platform as resistant to advanced artificial intelligence (AI) decryption models. The breakthrough supports Signal Advance’s mission to deliver next-generation, physics-based cybersecurity solutions designed to defend against both AI-driven and quantum-era threats. Listen to CEO Now!

Achieved key operational milestones establishing manufacturing capabilities to supply more than 2x the products required to achieve 2026 revenue targets

Initial target markets for commercialization include Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia

Initial target markets for commercialization include Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia

BERKELEY, Calif, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, announces its second $1 million investment in digital treasury assets to hedge against macroeconomic uncertainties, in line with the Company’s treasury management strategy.